Day: August 4, 2021

NOT FOR DISSEMINATION TO U.S. WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Aug. 04, 2021 (GLOBE NEWSWIRE) — Gran Colombia Gold Corp. (TSX: GCM; OTCQX: TPRFF) announced today that it has successfully priced an oversubscribed offering of US$300 million in senior unsecured notes due 2026 at a coupon rate of 6.875% (the “2026 Notes”) pursuant to Rule 144A and Regulation S of the U.S. Securities Act of 1933, as amended, (the “Act”), with closing expected to occur on or about August 9, 2021. The proceeds from the 2026 Notes will be used to (i) to fund the development of our Guyana operations, (ii) to prepay the remaining Gold-Linked Notes, and (iii) for general corporate purposes. The 2026 Notes have been assigned a rating of B+ by Fitch Ratings and a rating of B+ by S&P Global Ratings. This press release is...

Collaboration will initially explore the therapeutic potential of a combination of Imugene’s CF33-CD19 oncolytic virus (onCARlytics) and Celularity’s CD19 targeting chimeric antigen receptor (CAR) placental-derived investigational T-cell therapy, CyCART-19 Nonclinical in vitro and in vivo combination studies to commence in 2021 Celularity’s off-the-shelf allogeneic CD19 therapy has shown sustained T-cell growth with continuous killing of tumor cells in vivo1 Combining Imugene’s oncolytic virus technology with Celularity’s allogeneic CAR T-cell therapy has the potential to become a novel approach to improve outcomes for patients with solid tumorsSYDNEY, Australia and FLORHAM PARK, N.J., Aug. 04, 2021 (GLOBE NEWSWIRE) — Imugene Ltd (“Imugene”) (ASX: IMU), a clinical stage immuno-oncology company and Celularity Inc. (“Celularity”)...

CALGARY, Alberta, Aug. 04, 2021 (GLOBE NEWSWIRE) — Black Diamond Group Limited (“Black Diamond”, the “Company” or “we”), (TSX:BDI), a leading provider of space rental and workforce accommodation solutions, today announced its operating and financial results for the three and six months ended June 30, 2021 (the “Quarter”) compared with the three and six months ended June 30, 2020 (the “Comparative Quarter”). All financial figures are expressed in Canadian dollars. In the second quarter of 2021, Black Diamond reported consolidated revenue of $68.9 million, Adjusted EBITDA of $13.5 million, and core rental revenue of $23.2 million. Key Highlights from the Second Quarter of 2021Generated consolidated revenue of $68.9 million and Adjusted EBITDA of $13.5 million, up 85% and...

Record Total Company Revenue of $309.5 Million, 12.7% Higher than Last Year and 6.5% Higher Sequentially Electronic Materials Segment Revenue of $251.1 Million, 13.9% Higher than Last Year and 3.5% Higher Sequentially Expecting Total Company Revenue for Fourth Quarter Fiscal 2021 to be Approximately Flat Sequentially Full Year Adjusted EBITDA Guidance Range Revised to Between $355 Million and $365 MillionAURORA, Ill., Aug. 04, 2021 (GLOBE NEWSWIRE) — CMC Materials, Inc. (Nasdaq: CCMP), a leading global supplier of consumable materials primarily to semiconductor manufacturers, today reported financial results for its third quarter of fiscal 2021, which ended June 30, 2021. “Our CMC Materials team delivered another quarter of solid results, posting record revenue. Within Electronic Materials, we are particularly proud of the...

MELBOURNE, Australia, Aug. 04, 2021 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) announces today that the first patient has been dosed in its ‘CUPID’ first-in-human Phase I study of the Company’s next generation prostate cancer therapy candidate TLX592 in patients with advanced prostate cancer. The objective of the CUPID (64Cu PSMA Imaging and (Bio)Distribution) study is to evaluate the safety, tolerability, pharmacokinetics, biodistribution and radiation dosimetry of TLX592. This investigational agent will become Telix’s first targeted alpha therapy (“TAT”) for the treatment of patients with advanced prostate cancer. The CUPID study, which is being conducted in collaboration with GenesisCare, will recruit up to 15 patients and will initially use copper-64 (64Cu)-labelled TLX592, as a positron...

THE WOODLANDS, Texas, Aug. 04, 2021 (GLOBE NEWSWIRE) — LGI Homes, Inc. (NASDAQ: LGIH) today announced it closed 930 homes in July 2021, up from 611 homes closed in July 2020, representing year-over-year growth of 52.2%. The Company ended the first seven months of 2021 with 6,347 home closings, a 42.6% increase over 4,451 home closings during the first seven months of 2020. As of July 31, 2021, the Company had 103 active selling communities. About LGI Homes, Inc. Headquartered in The Woodlands, Texas, LGI Homes, Inc. engages in the design, construction and sale of homes in Texas, Arizona, Florida, Georgia, New Mexico, Colorado, North Carolina, South Carolina, Washington, Tennessee, Minnesota, Oklahoma, Alabama, California, Oregon, Nevada, West Virginia, Virginia and Pennsylvania. Since 2018, LGI Homes has been ranked as the 10th...

Press Release Atos to assist Federal Government Agencies to take full advantage of Artificial Intelligence Melbourne, Australia, August 5, 2021 – Atos has been appointed to the Australian Federal Government’s Digital Transformation Agency Hardware Marketplace to support government agencies in tackling enterprise digital challenges and to enable them to take full advantage of Artificial Intelligence. “As digital transformation of public services is already happening, accelerated by Covid-19 pandemic, the amount of data generated is gigantic. To generate trust and to provide leadership in these times of profound challenges and disruptions, Governments need to ensure their citizen that their data is processed in a secure and intelligent way.” said Mike Green, Managing Director of Atos in Australia. “We are really pleased to be part of the...

CALGARY, Alberta, Aug. 04, 2021 (GLOBE NEWSWIRE) — Crew Energy Inc. (TSX: CR) (“Crew” or the “Company”) is pleased to announce our operating and financial results for the three and six month periods ended June 30, 2021, and the release of our inaugural Environmental, Social and Governance (“ESG”) Report. Crew’s Financial Statements and Notes, as well as Management’s Discussion and Analysis (“MD&A”) for the three and six month periods ended June 30, 2021 are available on Crew’s newly designed website at www.crewenergy.com and filed on SEDAR at www.sedar.com. Two-year sustainability plan on track1: Crew is now targeting adjusted funds flow (“AFF”)3 in 2021 and 2022 between $310 and $350 million on spending of $220 to $265 million, supporting the generation of $95 to $140 million of 2022 annual AFF3 in excess of capital expenditures....

VANCOUVER, British Columbia, Aug. 04, 2021 (GLOBE NEWSWIRE) — Calibre Mining Corp. (TSX: CXB; OTCQX: CXBMF) (“Calibre” or the “Company”) announces financial and operational results for the three and six months ended June 30, 2021. The interim consolidated financial statements and management discussion and analysis can be obtained from www.sedar.com and the Company’s website, www.calibremining.com. All figures are expressed in U.S. dollars. Q2 2021 MILESTONES AND HIGHLIGHTSGold production of 43,506 ounces; Gold sales of 43,682 ounces generating $78.8 million in revenue at an average realized price(1) of $1,804 per ounce; Net income of $11.9 million with basic net income per share of $0.04; Cash on hand of $66.3 million at June 30, 2021, an increase of $8.1 million from Q1 2021; Consolidated Total Cash Costs(1) and All-in Sustaining...

LEXINGTON, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced plans to participate in the upcoming Canaccord Genuity 41st Annual Growth Conference. Management is scheduled to present Wednesday, August 11, 2021, at 3:00pm ET. Interested parties may access a live and recorded webcast of the presentation on the “Investors” section of the Company’s website at www.t2biosystems.com. About T2 BiosystemsT2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Candida® Panel, the T2Bacteria® Panel, the T2Resistance™ Panel,...